Non‐selective beta‐blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow‐up

Non‐cardioselective beta‐blocker (NSBB) effects on mortality in cirrhosis are controversial. We evaluated the impact of NSBBs on mortality according to liver severity and mortality cause.

[1]  J. Bosch,et al.  Beta-blockers in cirrhosis: Evidence-based indications and limitations , 2019, JHEP reports.

[2]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[3]  J. Trebicka,et al.  EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.

[4]  Pramod Kumar,et al.  Does the dose and type of nonselective beta‐blocker really matter? , 2017, Hepatology.

[5]  M. Mandorfer,et al.  Beta adrenergic blockade and decompensated cirrhosis. , 2017, Journal of hepatology.

[6]  V. de Lédinghen,et al.  Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination? , 2017, Alimentary pharmacology & therapeutics.

[7]  J. Bosch,et al.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases , 2017, Hepatology.

[8]  D. Christodoulou,et al.  Propranolol use beyond 6 months increases mortality in patients with Child‐Pugh C cirrhosis and ascites , 2016, Hepatology.

[9]  F. Bendtsen,et al.  Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[10]  G. D’Amico,et al.  Beta‐blockers in 2016: Still the safest and most useful drugs for portal hypertension? , 2016, Hepatology.

[11]  A. Krag,et al.  Keep the sick from harm in spontaneous bacterial peritonitis: Dose of beta blockers matters. , 2016, Journal of hepatology.

[12]  D. Christodoulou,et al.  Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child–Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use , 2016, Gut.

[13]  M. Poca,et al.  Development of hyperdynamic circulation and response to β‐blockers in compensated cirrhosis with portal hypertension , 2016, Hepatology.

[14]  David Moher,et al.  STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies , 2015, BMJ : British Medical Journal.

[15]  R. Heaney,et al.  Effect of Ebola Progression in Liberia , 2015, Annals of Internal Medicine.

[16]  A. Qamar,et al.  Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study , 2014, Digestive Diseases and Sciences.

[17]  W. Gelson,et al.  Beta‐blockers in cirrhosis patients with refractory ascites , 2014, Hepatology.

[18]  C. Mélot,et al.  Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites , 2010, Hepatology.

[19]  F. Oberti,et al.  A novel panel of blood markers to assess the degree of liver fibrosis , 2005, Hepatology.

[20]  D. Valla,et al.  Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. , 1999, European journal of gastroenterology & hepatology.

[21]  A. Ravaud,et al.  Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. , 1989, British journal of clinical pharmacology.

[22]  M. Arthur,et al.  Pharmacology of propranolol in patients with cirrhosis and portal hypertension. , 1985, Gut.

[23]  R. de Franchis.  Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. , 2015, Journal of hepatology.

[24]  R. de Franchis.  Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. , 2005, Journal of hepatology.

[25]  J. Fermanian,et al.  Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. , 1990, Gastroenterology.